IMPORTANCE Circulating tumor cells (CTCs) represent the liquid component of solid tumors and are a surrogate marker for residual cancer burden. Although CTC status is prognostic of recurrence and death in breast cancer, its role in guiding clinical management remains unknown.
O f the 255 000 new breast cancer diagnoses made in the United States annually, more than 60% are confined to the breast. 1 Despite improving survival rates, 20%
to 30% of patients with primary breast cancer will experience locoregional or distant disease recurrence. 2 Prospective identification of patients at higher risk of recurrence remains challenging owing to imperfect risk stratification. Although multiple-gene expression panels provide predictive information regarding the benefit of chemotherapy in patients with estrogen receptor (ER)-positive breast cancer, similar advances have not been achieved for the benefit of radiotherapy (RT).
3
Circulating tumor cells (CTCs) represent the liquid component of solid tumors and indicate the presence of residual disease. Circulating tumor cells are detected in 10% to 30% of patients with nonmetastatic breast cancer. [4] [5] [6] [7] Positive CTC status has been validated as prognostic of recurrence-free survival (RFS), breast cancer-specific survival, and overall survival (OS) in breast cancer. [6] [7] [8] [9] [10] [11] [12] The detection of even a single CTC has been shown to be prognostic of shorter RFS and OS. 7,10,13,14 Circulating tumor cell status has also been shown to be prognostic of failure of locoregional and adjuvant systemic treatments. 9,15-17 Furthermore, CTC status has been demonstrated to be prognostic of metastasis and survival in lowrisk patients with node-negative disease who did not receive adjuvant therapy. 12 No data are yet available regarding CTC status as a predictive factor of the benefit of RT in early-stage breast cancer. To test this concept, survival analyses were performed to test the associations and interactions of CTC status and RT with survival outcomes in patients from the National Cancer Database (NCDB). An external validation was performed using an independent patient cohort from the German SUCCESS (Simultaneous Study of GemcitabineDocetaxel Combination Adjuvant Treatment as well as Extended Bisphosphonate and Surveillance) clinical trial.
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Methods

Data Sources
The NCDB is a nationwide, facility-based comprehensive oncology database established by the Commission on Cancer of the American College of Surgeons and the American Cancer Society in 1989. 18 The institutional review board of Northwestern University Feinberg School of Medicine determined that local institutional review board approval and informed consent is not required for NCDB analyses. The SUCCESS trial (NCT02181101) was a prospective, multicenter, phase 3 trial of women with nonmetastatic breast cancer and at least 1 high-risk factor randomized to 1 of 2 chemotherapy regimens. 7, 19 Defining the prognostic significance of CTCs was a study objective. 7 The SUCCESS trial was approved by 37
German ethical boards (lead ethical board: LudwigMaximilians-University, Munich) and conducted in accordance with the Declaration of Helsinki. 20 Deidentified data from the SUCCESS cohort were provided upon request by W.J. for this post hoc secondary analysis. 7 Written informed consent was obtained for each patient. Only deidentified data from the SUCCESS cohort were obtained for this secondary analysis, which according to the Common Rule, is not human subjects research and does not require institutional review board approval.
7
In accordance with the SUCCESS trial, blood samples were obtained before adjuvant therapy for evaluation of CTCs using CellSearch. 22 CellSearch is the only platform for CTC detection that is approved by the US Food and Drug Administration for estimation of prognosis in metastatic disease. To date, no evidence supports a role for CTCs in predicting response to therapy. Further information on the design of the SUCCESS trial design has been described previously 7 and is described briefly in the eMethods in the Supplement.
Cohort Selection and Variable Definition
Patients with stages pT1 to pT2 and pN0 to pN1 (microscopic) breast cancer and listed as having positive or negative CTC status in the NCDB from January 1, 2004 , to December 31, 2014, and patients with pT1 to pT2 and pN0 to pN1 breast cancer from the SUCCESS trial were included from September 1, 2005, through September 30, 2013 (eFigure 1 in the Supplement). The NCDB began reporting CTC status in 2004 after approval of CellSearch by the US Food and Drug Administration, but most participants (97.7%) were diagnosed after 2010.
We performed multivariable analyses of the NCDB and SUC-CESS overall cohorts. To have enough patients to perform subset analyses of women grouped by type of surgery, the 2 overall cohorts were pooled for subset analyses. Two-to-one (NCDB) or 3-to-1 (SUCCESS) nearest-neighbor propensity score matching was performed to generate well-balanced, matched cohorts of patients based on CTC status (eTables 1-4 in the Supplement). 23 Multivariable parametric accelerated failure time models using the generalized gamma distribution were used to evaluate the association of CTC status and RT with local RFS (LRFS), disease-free survival (DFS), and/or OS. This model was chosen in place of the Cox proportional hazards model owing to violation of the proportional hazards assumption among CTCpositive patients who received vs did not receive RT. When the non-proportional hazards assumption is present, the parametric accelerated failure time model provides better goodness-offit of the model to the observed data and therefore provides more robust statistical inference. [24] [25] [26] [27] The accelerated failure time model estimates the time ratio (TR), which describes the factor by which the time to event is associated between 2 groups. A TR of greater than 1 therefore describes longer survival.
Covariates used in analyses were selected a priori based on clinical knowledge and availability (eTables 5-10 in the Supplement). Use of chemotherapy was included as a covariate in the multivariable analyses of the NCDB cohort. Type of chemotherapy was included as a covariate in the multivariable analyses of the SUCCESS trial. Because the primary outcomes of the SUCCESS trial have yet to be published, survival estimates associated with type of chemotherapy were not listed. Type of surgery was omitted in the analyses of the individual cohorts owing to its strong association with receipt of RT, but this factor was addressed by performing subset analyses of the pooled cohort by type of surgery. Models including surgery as a covariate were also performed and did not change the findings as reported.
We combined CTC status and RT in a composite variable to calculate survival estimates relative to the reference level (CTC positive without RT). The main effects and pairwise interaction terms of CTC status and RT were tested for all models. Subgroup analyses by CTC status were performed. Propensity score-matched and inverse probability-weighted cohort accelerated failure time multivariable analyses were also performed to reduce treatment assignment biases related to measured covariates. 23 All statistical tests were 2-tailed. To test the robustness of the observed results, we explored the sensitivity of TR estimates to a possible unmeasured confounder. 28 Statistical analyses were performed using R software (version 3.3.3) with the MatchIt, survival, flexsurv, Hmisc, and rms packages. 
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Results
Characteristics of Cohorts
Kaplan-Meier Estimates
We calculated unadjusted estimates of survival proportions and restricted mean survival times for all analyses ( Table 2 and eTables 5-10 in the Supplement). Survival curves were plotted as unadjusted Kaplan-Meier estimates ( Figure 1, Figure 2 , and eFigure 2 in the Supplement). The CTC-positive patients without RT had significantly shorter 4-year OS compared with CTC-positive patients with RT and CTC-negative patients without and with RT in the NCDB cohort (88.0%; 95% CI, 82.3%-94.2%; P = .005) and shorter 5-year LRFS (85.7%; 95% CI, 73.6%-99.8%; P = .003), DFS (75.2%; 95% CI, 61.5%-91.9%; P = .002), and OS (84.5%; 95% CI, 72.7%-98.2%; P = .008) in the SUCCESS cohort. Similarly, CTC-positive patients without RT from the pooled cohort who underwent breastconserving surgery (BCS) had significantly shorter 5-year OS (73.3%; 95% CI, 59.4%-90.3%; P < .001) compared with CTCpositive patients with RT and CTC-negative patients without and with RT (Table 2 and eTable 9 in the Supplement). No significant difference was noted in 5-year OS among patients who underwent mastectomy, regardless of CTC status or receipt of RT (84.3%; 95% CI, 76.0%-93.6%; P = .30) ( Table 2 and eTable 10 in the Supplement).
Multivariable Survival Analyses
In the NCDB cohort, we found a significant interaction of CTC status and use of RT with 4-year OS (94.9% for CTC-positive RT vs 88.0% for CTC-positive non-RT vs 93.9% for CTCnegative RT vs 93.4% for CTC-negative non-RT; P < .001) ( compared with those who did not receive RT (TR, 2.03; 95% CI, 1.52-2.71; P < .001). In subset analyses, CTC-positive patients with RT had significantly longer OS compared with CTCpositive patients without RT (TR, 2.04; 95% CI, 1.55-2.67; P < .001) ( Table 3) . Receipt of RT, however, was not associated with longer OS in CTC-negative patients (TR, 0.80; 95% CI, 0.52-1.25; P = .33) (Table 3 and Figure 1 ). d For pairwise interaction terms of CTC status and RT in the AFT multivariable analyses, P = .01 for all patients (n = 1697) and P < .001 for matched cohorts (n = 1197).
e For AFT multivariable analysis, includes 1516 for all patients and 1176 for matched cohorts.
f For pairwise interaction terms of CTC status and RT in the AFT multivariable analysis, P = .04 for all patients and P = .04 for matched cohorts.
g For pairwise interaction terms of CTC status and RT in the AFT multivariable analysis, P = .13 for all patients and P = .20 for matched cohorts.
h For pairwise interaction terms of CTC status and RT in the AFT multivariable analysis, P = .16 for all patients and P = .23 for matched cohorts.
i For pairwise interaction terms of CTC status and RT in the AFT multivariable analysis, P = .04 for all patients (n = 2177) and P < .001 for matched cohorts (n = 1840).
j For pairwise interaction terms of CTC status and RT in the AFT multivariable analysis, P = .82 for all patients (n = 1036) and P = .83 for matched cohorts (n = 932). (Table 3) . In a pooled analysis of patients from the NCDB and SUCCESS cohorts who underwent BCS, we found a significant interaction of CTC status and use of RT with OS (93.6% for CTC-positive RT vs 73.3% for CTC-positive non-RT vs 95.5% for CTC-negative RT vs 92.7% for CTC-negative non-RT groups; P < .001) ( Table 2 and eTable 9 in the Supplement). Among patients who underwent mastectomy, however, no significant interaction between CTC status and receipt of RT with OS was found (88.3% for CTC-positive RT vs 84.3% for CTC-positive non-RT vs 95.8% for CTC-negative RT vs 91.0% for CTCnegative non-RT groups; P = .83) ( Table 2 and eTable 10 in the Supplement). After BCS, CTC-positive patients with RT experienced longer OS compared with CTC-positive patients without RT (TR, 4.37; 95% CI, 2.71-7.05; P < .001) ( Table 3) . However, CTC-negative patients with RT did not have longer OS Figure 2 ). Of the patients who underwent mastectomy, receipt of RT was not associated with an OS benefit in CTC-positive (TR, 0.92; 95% CI, 0.45-1.88; P = .82) or CTC-negative (TR, 1.05; 95% CI, 0.62-1.77; P = .86) patients (Table 3 and Figure 2 ). Sensitivity analyses demonstrated that TR estimates for longer survival among patients with CTC-positive status who received RT were robust when tested by the introduction of possible unmeasured confounding (eTable 15 in the Supplement).
Discussion
In this analysis of a large cohort of patients with early-stage breast cancer and known CTC status from the NCDB, CTC status was predictive of a benefit of RT for OS. This finding was validated and extended in an independent cohort of patients from the German phase 3 SUCCESS trial, in which CTC status was predictive of a benefit of RT for LRFS, DFS, and OS in patients treated with surgery followed by systemic therapy. In both cohorts, CTC-positive patients who received RT had longer OS compared with CTC-positive patients who did not receive RT. In the SUCCESS trial, CTC-positive women derived a large benefit in LRFS and DFS from RT, whereas CTCnegative women did not. In a pooled analysis of patients from both cohorts who underwent BCS, receipt of RT was associated with longer OS in CTC-positive patients but not in CTCnegative patients. Among patients who received mastectomy, however, CTC status was not associated with an OS benefit from RT. Determination of CTC status may therefore be useful as a predictive marker for potential benefit from RT in patients with early-stage breast cancer who receive BCS. Postoperative RT is the standard of care for most patients undergoing BCS. 3 The benefit of whole-breast RT on locoregional recurrence has been consistently demonstrated in prospective clinical trials, 36,37 whereas a comprehensive metaanalysis of prospective trials revealed an OS advantage associated with RT. 2 More recently, investigators have moved toward identifying low-risk patients for whom RT may not The present study suggests that CTC status may be useful alongside standard clinicopathologic variables to better select patients with early-stage breast cancer for whom RT may be of benefit. This finding may be particularly relevant for patients with lower-risk disease who are considering omission of RT after BCS. Most patients analyzed within the pooled cohort who underwent BCS and did not receive RT were older and had low-grade, ER-positive, ERBB2-nonamplified tumors that were smaller than 2 cm and did not have nodal involvement, reflecting a favorable patient population for whom omission of RT may reasonably be considered. Although the biological underpinning of the predictive value of CTC status with RT benefit is not immediately clear, CTC positivity may indicate a higher burden of locoregional residual disease or an association with endocrine resistance. In support of this, in the SUCCESS trial, the risk of local recurrence was higher in CTC-positive women who did not receive RT. Although CTC status was associated with benefit of RT among patients who underwent BCS, it was not associated with benefit of RT among patients who underwent mastectomy. This finding suggests that benefit of RT among CTC-positive patients may be limited to those who undergo BCS, perhaps owing to the higher burden of residual local disease in these patients. Additional studies are required to elucidate the potential mechanisms underlying the association of positive CTCs with increased risk of local recurrence.
Limitations
The NCDB is a valuable resource that permits analysis of rare cancers, treatment paradigms, and prognostic variables. 18 Although the size of the NCDB cohort used here is large compared with most other studies evaluating CTC status, this analysis remains limited by the small proportion of patients within the NCDB who underwent evaluation for CTCs. Importantly, CTC-positive patients who did not receive RT were not found to be older or to have higher comorbidity scores, nor was RT more commonly omitted against recommendation in CTCpositive patients. The small sample size is a particular limitation when analyzing patients with early-stage breast cancer owing to infrequent recurrences or death, further limiting the Furthermore, CTCs are known to demonstrate remarkable molecular heterogeneity with significant intrapatient and interpatient variability. 55-57 Specific genotypic and phenotypic features of CTCs may therefore further inform their prognostic and predictive potential. Of importance, however, the observed associations within these analyses were robust to plausible levels of unmeasured confounding.
The particular limitations of the NCDB cohort are less concerning given that we observed consistent results by performing an external validation using data from the SUCCESS trial in which all patients were prospectively evaluated for CTC status. The SUCCESS trial is, to date, the largest clinical trial in which CTC status was evaluated in women with earlystage breast cancer. This trial validated CTC status as independently prognostic of longer survival in early-stage breast cancer. 7 Despite the limitations of the NCDB and SUCCESS cohort analyses as well as the modest differences between the inclusion criteria, both cohorts gave remarkably similar results, producing a robust external validation.
Conclusions
These analyses provide initial evidence for the use of CTC status as a predictive marker for benefit of RT in patients with early-stage breast cancer. 
SUCCESS Trial
The Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance (SUCCESS) trial was a prospective randomized Phase III trial (EUDRA-CT No. 2005-000490-21).
Eligible patients included women with pT1-T4, pN0-N3, M0 breast cancer considered to be average-or high-risk for whom chemotherapy was recommended. All women had at least one of the following high-risk factors: histopathological proof of axillary lymph node metastases (pN1-3), tumor size ≥pT2, histological grade 3, negative hormone receptor status, or age ≤35 years. Women were randomized to receive adjuvant fluorouracil-epirubicin-cylcophosphamide (FEC; 500/100/500mg/m 2 ) followed by three cycles of docetaxel (100mg/m 2 ) every 3 weeks or three cycles of FEC followed by 3 cycles of gemcitabine (1000mg/m 2 d1,8)-docetaxel (75mg/m 2 ) every 3 weeks. 7 Following the completion of chemotherapy, the patients were further randomized to receive either 2 or 5 years of zoledronate.
Surgery consisted of either breast conserving surgery (BCS) or mastectomy with R0 resection. Sentinel node dissection was performed in all patients without clinical evidence of nodal disease followed by complete axillary node dissection in patients with positive sentinel nodes. Patients with clinical evidence of nodal disease received axillary lymph node dissection. Radiotherapy consisted of treatment of the breast or chest wall using tangential opposition beams to a total dose of 50.4 Gy in 1.8 Gy daily fractions. A boost was given at the discretion of the individual investigator. Irradiation of the axillary lymph nodes was not permitted for patients with three or less positive lymph nodes.
Detection of CTCs
SUCCESS trial: Following resection, but prior to adjuvant therapy, blood was collected for identification of CTCs on 1,994 patients using the CellSearch system®. 19 CTCs were evaluated using the CellSearch System (Veridex, Raritan, NJ) as previously reported.
1 Thirty (30) milliliters of peripheral blood was collected into three CellSave tubes, and 7.5mL of the centrifuged buffy coat was processed. The samples with at least one positive CTC per 30mL of peripheral blood collected was considered CTC-positive.
Variable Definition
Variables were defined as follows: Lymphovascular Invasion (LVI): "Negative," or "Positive." Histology: ductal ("IDC"), lobular or mixed ("ILC/Mixed"), or "Other." Type of surgery: breast conserving surgery ("BCS"), or mastectomy "Mastectomy." Race: "White" or "Black/Other." Hispanic ethnicity: "No" or "Yes." Insurance status: "Private", "Government," or "None." CharlsonDeyo comorbidity score: "0", "1", or "2". Prior cancer: "No" or "Yes." Facility type: "Academic," "Community", "Comprehensive," or "Integrated." Income quartile, defined by NCDB based on the median household income within the patient's zip code: Top", "2 nd ", "3 rd ", "Bottom." Education quartile, defined by NCDB based on the number of adults in the patient's zip code who did not graduate from high school: "Top", "2 nd ", "3 rd ", "Bottom." Population: "Urban" or "Nonurban." Menopausal status: "Pre-menopausal" or "Postmenopausal." A new variable was made combining CTC-status and radiotherapy. All variables were checked for consistency. Missing data was coded as "Unknown."
Definition of Outcomes
Local Recurrence-Free Survival (LRFS) and Disease-Free Survival (DFS) were defined as per the SUCCESS trial. LRFS was defined as any relapse in the area of surgery between the sternum and anterior axillary line below the inferior clavicular fossa and above the 7 th rib, including involvement of the pectoral muscles, serratus lateralis muscles, or the oblique externus muscle. DFS was defined as invasive disease recurrence, second primary tumors, and death from any cause.
Multivariable Models
In each multivariable analysis, inclusion of CTC-status as a covariate led to decreased Akaike Information Criterion (AIC) values, indicating that inclusion of CTC improves the model compared to a model in which radiotherapy alone is considered, while inclusion of the interaction variable decreased AIC values yet further. 
